Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Levodopa

Drug class: Aromatic Amino Acid

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Levodopa used for?
The FDA-approved label (Inbrija, Merz Pharmaceuticals, LLC, July 20, 2026) says: “INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Levodopa have a boxed warning?
No. None of the 2 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Levodopa?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Levodopa been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Levodopa?
1 company lists prescription products of Levodopa in the FDA NDC Directory, including Merz Pharmaceuticals, LLC.

What Levodopa is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa

— FDA label: Inbrija, Merz Pharmaceuticals, LLC, effective July 20, 2026. Read the full label on DailyMed →

The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 2 FDA labels for this medicine have a boxed warning.

Forms and how it is given

Dosage formsCapsule
RouteRespiratory (inhalation)
Prescription products2 in the FDA NDC Directory
Brand namesInbrija

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA209184
INBRIJA
MerzDecember 21, 2018 5, latest July 7, 2026
2026: Labeling · 2026: Labeling · 2020: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2107616, 2107621
SPL set ID of the quoted label077c0f39-a3a2-4b2b-a184-09131889dcfb
FDA labels (SPL)2
FDA applicationsNDA209184
Active ingredients (FDA)LEVODOPA

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Inbrija, Merz Pharmaceuticals, LLC, effective July 20, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers